|
KMID : 1009020210190010174
|
|
Clinical Psychopharmacology and Neuroscience
2021 Volume.19 No. 1 p.174 ~ p.178
|
|
|
Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases
|
|
De Berardis Domenico
Rapini Gabriella
Olivieri Luigi
Giardini Agostina
De Lauretis Ida
Serroni Nicola
Orsolini Laura
Fornaro Michele
Iasevoli Felice
Trotta Sabatino
|
|
|
Abstract
|
|
|
|
Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D2/D3 receptors with preferential binding to the D3 receptor, antagonism of 5HT2B receptors, and partial agonism of 5HT1A. Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.
|
|
|
KEYWORD
|
|
|
Cariprazine, Clozapine, Effectiveness, Efficacy, Schizophrenia, Tolerability
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|